Thousands of Americans who rely on chlorthalidone to manage high blood pressure are being urged to check their medication bottles after a nationwide recall was announced earlier this month. The voluntary recall, initiated by Inventia Healthcare Limited of Mumbai, India, and distributed across the United States by Rising Pharma Holdings, Inc. of East Brunswick, New Jersey, affects more than 11,000 bottles of the popular blood pressure drug. The move comes after the U.S. Food and Drug Administration (FDA) determined that certain batches of the medication failed crucial quality tests, raising concerns about their effectiveness.
On June 5, 2026, the FDA reported that 11,460 bottles of chlorthalidone tablets, USP, 25 mg, were being pulled from pharmacy shelves due to "failed dissolution specifications." According to the FDA, dissolution testing is a standard measure to assess how quickly and completely a drug dissolves and releases its active ingredients when placed in liquid. This process is essential for ensuring that patients receive the intended dose and therapeutic effect every time they take their medication. As pharmaceutical technology company Pion explains, dissolution tests "assess the performance and quality of different drug formulations, as well as to ensure consistency in drug release between different batches."
The recall affects two specific types of packaging: 100-count bottles with batch code RISA24001 and 1,000-count bottles with batch code RISB24002. Both batches carry an expiration date of April 2027. These bottles were distributed nationwide, meaning patients across the country could be impacted. The FDA's enforcement report and coverage from NewsNation confirm that no press release was issued as of June 22, 2026, but the recall is ongoing and the agency has since classified it as a "Class II" recall. This classification indicates a moderate hazard, where use of the recalled product may cause temporary or medically reversible adverse health effects.
Chlorthalidone is a widely prescribed diuretic medication. According to the Cleveland Clinic and Mayo Clinic, it is used to treat high blood pressure—also known as hypertension—and to reduce swelling (edema) associated with heart, kidney, or liver disease. The drug works by helping the kidneys remove excess water and salt from the body, which is then excreted in urine. Managing blood pressure effectively is crucial for reducing the risk of heart attacks, strokes, and other serious health complications. For many patients, chlorthalidone is a daily necessity.
The heart of the issue lies in the failed dissolution testing. Tablets that do not dissolve properly in the body may not release their active ingredient as intended. This could significantly reduce the drug's effectiveness, leaving patients with uncontrolled blood pressure or persistent fluid retention. As the FDA and pharmaceutical experts note, while the risk of immediate harm is considered low, the potential for compromised treatment is a major concern. According to FOX Business, "failure means the drug may not dissolve properly, reducing effectiveness."
It's important to note that, as of June 22, 2026, the FDA had not assigned the recall to the most severe category (Class I), which is reserved for situations involving a potentially life-threatening hazard. Instead, the Class II designation suggests that while the defect is not expected to cause permanent harm, it could result in temporary health issues if the medication does not work as intended. NewsNation reports that the FDA's recall classes range from Class I (most serious) to Class III (least serious), with the current recall falling in the middle.
For patients, the immediate advice is clear: do not stop taking your prescribed medication without first consulting your healthcare provider. The Cleveland Clinic and the American Heart Association both stress that abruptly discontinuing blood pressure medication can result in serious health risks, including spikes in blood pressure that could lead to emergency situations. Instead, patients should check their prescription bottles for the affected batch codes and expiration dates. If their medication matches the recalled product, they are urged to contact their doctor or pharmacist to discuss safe alternatives or next steps.
As of June 23, 2026, the recall was ongoing and no official press release had been issued by either Inventia Healthcare Limited or Rising Pharma Holdings, Inc. FOX Business reached out to both companies for comment but had not received a response at the time of reporting. The FDA's recall page continues to update the status as new information becomes available.
This latest recall comes less than a year after another high-profile blood pressure medication, prazosin hydrochloride, was pulled from the market due to contamination with potentially cancer-causing chemicals. In that case, more than half a million bottles were affected, highlighting the ongoing challenges pharmaceutical companies face in maintaining quality control across large-scale manufacturing operations.
For many, the recall serves as a reminder of the importance of drug safety and the rigorous testing that medications undergo before reaching consumers. Dissolution testing, while technical, plays a vital role in ensuring that drugs perform as expected once inside the human body. According to pharmaceutical company Pion, "dissolution tests measure the release rate of a drug and its active ingredient from the tablet or capsule used as a dosage when it's placed into a liquid to assess the performance and quality of various drug formulations and batches." When these tests are not met, recalls like this one become necessary to protect patient health.
Healthcare providers are now on alert, advising patients to remain vigilant but calm. The FDA and leading health organizations reiterate that the recall is a precautionary measure aimed at preventing potential lapses in blood pressure control, not a cause for panic. Patients are encouraged to reach out to their healthcare teams with any questions or concerns and to bring their medication bottles to appointments for verification.
For those affected, the next steps may involve switching to a different batch of chlorthalidone or an alternative blood pressure medication, based on their doctor's recommendation. Pharmacies are working closely with manufacturers and distributors to remove the recalled products from shelves and ensure that safe, effective alternatives are available to those who need them.
As the recall continues to unfold, the FDA and other health authorities will be monitoring the situation closely, ready to provide further guidance as more information emerges. For now, the message is simple: check your medication, consult your healthcare provider, and don't make any changes to your treatment plan without professional advice. The recall may be unsettling, but with careful attention and communication, patients can continue to manage their blood pressure safely and effectively.
With quality assurance in the pharmaceutical supply chain under fresh scrutiny, this episode underscores the critical importance of vigilance—from manufacturers to regulators to patients themselves—in safeguarding public health.